These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 31671770)

  • 21. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology.
    Rojo LE; Gaspar PA; Silva H; Risco L; Arena P; Cubillos-Robles K; Jara B
    Pharmacol Res; 2015 Nov; 101():74-85. PubMed ID: 26218604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fat Distribution in Schizophrenia Patients: A Pilot Study Comparing First- and Second-Generation Antipsychotics.
    Sapra M; Lawson D; Iranmanesh A
    J Clin Psychopharmacol; 2018 Feb; 38(1):68-71. PubMed ID: 29257787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain insulin action: Implications for the treatment of schizophrenia.
    Agarwal SM; Kowalchuk C; Castellani L; Costa-Dookhan KA; Caravaggio F; Asgariroozbehani R; Chintoh A; Graff-Guerrero A; Hahn M
    Neuropharmacology; 2020 May; 168():107655. PubMed ID: 31152767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential metabolic effects of antipsychotic treatments.
    Haupt DW
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S149-55. PubMed ID: 16872808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.
    Engl J; Laimer M; Niederwanger A; Kranebitter M; Starzinger M; Pedrini MT; Fleischhacker WW; Patsch JR; Ebenbichler CF
    Mol Psychiatry; 2005 Dec; 10(12):1089-96. PubMed ID: 16130009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study.
    Ilies D; Huet AS; Lacourse E; Roy G; Stip E; Amor LB
    Can J Psychiatry; 2017 Dec; 62(12):827-836. PubMed ID: 28673098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity.
    Heal DJ; Gosden J; Jackson HC; Cheetham SC; Smith SL
    Handb Exp Pharmacol; 2012; (212):135-64. PubMed ID: 23129331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism.
    Sertié AL; Suzuki AM; Sertié RA; Andreotti S; Lima FB; Passos-Bueno MR; Gattaz WF
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1884-90. PubMed ID: 21840366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats.
    Liu X; Wu Z; Lian J; Hu CH; Huang XF; Deng C
    Sci Rep; 2017 Jun; 7(1):2762. PubMed ID: 28584269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
    Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
    Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glucoregulation in normal weight schizophrenia patients treated by first generation antipsychotics].
    Marić N; Doknić M; Damjanović A; Pekić S; Jasović-Gasić M; Popović V
    Srp Arh Celok Lek; 2008; 136(3-4):110-5. PubMed ID: 18720742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.
    Henderson DC
    J Clin Psychiatry; 2008 Feb; 69(2):e04. PubMed ID: 18363448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
    Simon V; van Winkel R; De Hert M
    J Clin Psychiatry; 2009 Jul; 70(7):1041-50. PubMed ID: 19653979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.
    Lett TA; Wallace TJ; Chowdhury NI; Tiwari AK; Kennedy JL; Müller DJ
    Mol Psychiatry; 2012 Mar; 17(3):242-66. PubMed ID: 21894153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.